Focus on Flu with an Eye on Treatment

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. Physician assistants, nurse practitioners, primary care physicians, and other health care professionals can identify and help manage influenza in the community. Better diagnostic modalities, more effective treatments, and practical methods to control the spread of influenza are needed. Although diagnostic tests for influenza exist and are currently being utilized, newer modalities are emerging that have promising advantages. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Clinicians who evaluate patients must keep apprised of new information regarding the diagnosis and treatment of influenza so they can incorporate this information into practice, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will evaluate approved antiviral agents regarding their novel mechanisms of action and ability to reduce duration of clinical illness and complications. They also will incorporate didactic presentations, a case-based discussion, as well as GameOn!—a playable gaming activity where both knowledge and confidence are put to the test—to engage learners, thus facilitating better application of information into clinical practice.

Target Audience

The intended audience for this activity is primary care physicians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Apply new evidence into practice regarding the use of diagnostic testing for patients suspected of having influenza.
  • Differentiate current options for the treatment of influenza based on their efficacy and ability to reduce disease transmission.
  • Utilize antiviral agents as needed to treat patients who are at normal or high risk for complications from influenza.

Additional Information

Partner: 
myCME
State Relevance: 
Ohio
Pennsylvania
Illinois
District of Columbia
Maryland
Massachusetts
Course summary
Available credit: 
  • 2.00 MOC
  • 2.00 MOC II
  • 2.00 AMA PRA Category 1 Credit
Course opens: 
07/31/2020
Course expires: 
07/31/2021
Rating: 
0

Activity Chair

Lawrence Herman, DMSc(c), MPA, PA-C, DFAAPA
Past President, American Academy of PAs
President, Palantir Healthcare, LLC
Boiling Springs, SC

Dr. Herman discloses the following:
Speakers Bureau: Novo Nordisk

Faculty

Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Dr. Savoy discloses the following:
Honorarium: Merck Manual
Board of Directors: AAFP
 

Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor, Department of Family Medicine
Executive Director, Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA

Dr. Vega has no relevant financial relationships to disclose.

Conflict of Interest Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accredited Provider Disclosure

Vindico Medical Education Staff: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Reviewer Disclosures

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP has no relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD has no relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

This continuing medical education activity is provided by Vindico Medical Education.

AMA PRA Category 1 CreditTM

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part II Points:
Successful completion of this CME activity enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Within 60 days of the end of the activity. ABIM MOC Points will be reported on your behalf.

By providing your ABIM number, you consent to Vindico Medical Education and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS System.

AANP Contact Hours

Accreditation Statement

image

 

 

 

 

This activity is approved for 2.0 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20074345. This activity was planned in accordance with AANP Accreditation Standards and Policies.

AAPA Category I Credit

image

 

 

 

Accreditation Statement

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Designation Statement

This enduring material is approved for 1 year from the date of original release, July 31, 2020, to July 30, 2021.

Available Credit

  • 2.00 MOC
  • 2.00 MOC II
  • 2.00 AMA PRA Category 1 Credit
Please login or register to take this course.

This course is offered through myCME. To take this course you will be redirected to myCME's website. You must have an account with myCME in order to complete this activity. 

Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!

 

Topics

Pharmacology